Staphylococcus Aureus Network Adaptive Platform Trial
University of Melbourne
Summary
The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is an International Multi-Centered Randomised Adaptive Platform Clinical Trial to evaluate a range of interventions to reduce mortality for patients with Staphylococcus Aureus bacteraemia (SAB).
Description
Infection of the bloodstream with the bacterium Staphylococcus aureus (Staphylococcus aureus bacteraemia, SAB) is a serious infection that results in 15-30% of affected patients dying within three months of acquiring the infection. Treatment of this infection requires patients to be hospitalised, treated with prolonged antibiotics through an intravenous line, and carefully examined for the occurrence of complications associated with this condition. At present, there are many treatment options in current use, with no clear agreement as to which of these is best. The SNAP trial aims to identify…
Eligibility
- Age range
- Not specified
- Sex
- All
- Healthy volunteers
- No
PLATFORM Inclusion Criteria: Patients must fulfil all of the following criteria to be eligible to enter the SNAP trial: 1. Staphylococcus aureus complex grown from ≥1 blood culture 2. Admitted to a participating hospital at the time of eligibility assessment (OR if patient has died, they were admitted to this site anytime from the time of blood culture collection until the time of eligibility assessment) PLATFORM Exclusion Criteria: Potentially eligible participants meeting any of the following criteria at the time of eligibility assessment for platform entry will be excluded from the rand…
Interventions
- DrugCefazolin
Cefazolin
- DrugPenicillin
benzylpenicillin
- DrugClindamycin
Clindamycin
- DrugVancomycin
Vancomycin or Daptomycin
- OtherEffectiveness of early switch to oral antibiotics
This involves testing a strategy rather than individual antibiotic agents
- RadiationWhole body FDG PET/CT Imaging
Whole body FDG PET/CT imaging will be performed using a standardised protocol describing patient preparation and minimum specifications for radiopharmaceutical production, quality control, and PET/CT acquisition.
Locations (161)
- Houston Methodist Research InstituteHouston, Texas
- Canberra HospitalGarran, Australia Capital Territory
- Blacktown HospitalBlacktown, New South Wales
- Royal Prince Alfred HospitalCamperdown, New South Wales
- Concord Repatriation and General HospitalConcord, New South Wales
- St Vincent's Hospital SydneyDarlinghurst, New South Wales